Bayer's Masterstroke: Supreme Court Ruling and Ruveon Spin-Off Ignite a Record Rally

Bayer's shares jump 9% after creating Ruveon subsidiary for US glyphosate sales and securing a Supreme Court ruling that blocks thousands of cancer warning lawsuits.

Bayer is rewriting its playbook. The German conglomerate has carved out its embattled US glyphosate business into a dedicated subsidiary, Ruveon LLC, while simultaneously securing a landmark Supreme Court ruling that neutralises thousands of state-level cancer warning lawsuits. The one-two punch has propelled the stock to levels not seen in over a year.

Shares surged more than 9% in a single session, closing at €53.12 on Thursday and touching a fresh 52-week high of €53.20. That puts the equity just 0.15% below its peak for the period. Since plumbing a trough of €25.09 last August, Bayer has vaulted 111.68% higher. Year-to-date, the gain stands at 39.70%, with the stock more than doubling over the last twelve months.

Ruveon LLC, headquartered in St. Louis and led by Alfonso Alba Ordonez, is the centrepiece of a strategic overhaul. The new entity will manage all US sales of glyphosate-based products, effectively insulating Bayer’s core operations from the legal and reputational fallout that has dogged the group since its $63 billion acquisition of Monsanto. Markt beobachter see the move as a prelude to a full or partial divestiture, though for now Ruveon remains wholly owned. The restructuring is part of a five-year programme within the Crop Science division.

The legal breakthrough came on 25 June 2026, when the US Supreme Court ruled that federal law preempts state claims alleging inadequate cancer warnings on glyphosate, provided the Environmental Protection Agency has already reviewed the substance. The decision strips thousands of pending lawsuits of their legal foundation. Crucially, however, the ruling only applies to warning-related claims. More serious allegations — such as design defects and negligence — remain live.

Bayer is not stopping there. A proposed class settlement worth up to $7.25 billion is working its way through the courts, with a final hearing scheduled for 19 August 2026. The company has already set aside provisions in the double-digit billions to cover the cost. Analysts note that the settlement, if confirmed, would remove the largest overhang from the Monsanto legacy. Even so, free cash flow is expected to turn negative this year as the payouts take their toll.

The rally has attracted bullish attention from the sell side. Deutsche Bank’s Virginie Boucher-Ferte upgraded Bayer from “Hold” to “Buy” and raised her price target from €45 to €60, arguing that the legal overhang is evaporating and investors can now focus on the operational story.

That story has a pharma chapter too. First-quarter 2026 results showed strong momentum for Nubeqa and Kerendia, while the pipeline candidate asundexian is undergoing accelerated regulatory reviews in the United States, China, and Europe. The European Medicines Agency began its assessment in June. Bayer expects to return to mid-single-digit growth in pharmaceuticals from 2027.

Yet the euphoria carries warnings. The 14-day relative strength index stands at 85.2, deep in overbought territory. The 30-day volatility rate of 63.50% underscores how nervously the market is handling the stock. Historically, such RSI readings have often preceded a pause or pullback.

A fresh conflict is also brewing. Bayer has petitioned US authorities to impose anti?dumping and countervailing duties on Chinese glyphosate imports. American farming groups warn that the move could raise input costs for growers, potentially straining relationships with the very customers Bayer depends on for its core crop protection business. The tariff fight risks introducing a new headwind just as the legal winds turn favourable.

With a $7.25 billion settlement hearing in August, a new subsidiary to manage, and a pharma pipeline that needs to deliver, 2026 is shaping up as the decisive year for Bayer’s post-Monsanto identity. The stock has priced in the legal victory and the restructuring plan. Whether it can hold those gains will depend on execution, cash flow, and the final resolution of the last big liabilities.